ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Regulatory news

EU · EU licence (European Commission)

Remibrutinib (Rhapsido)

Rhapsido is indicated for the treatment of chronic spontaneous urticaria (CSU) in adult patients with inadequate response to H1 antihistamine treatment.

CHMP opinion 26 Feb 2026 → EU licence 23 Apr 2026 · Novartis Europharm Limited
US · FDA approval, new medicine

Remibrutinib (Rhapsido)

To treat chronic spontaneous urticaria in adults who remain symptomatic despite H1 antihistamine treatment

Approved 30 Sept 2025

Research

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.